Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025
SAN FRANCISCO and BOSTON, July 06, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics,…
The Dermatology Group of Arkansas Welcomes Double Board-Certified Dermatologist to Practice
LITTLE ROCK, Ark., July 04, 2025 (GLOBE NEWSWIRE) -- The Dermatology Group…
MEI Micro partners with Steadman Philippon Research Institute in new technology development
SANTA BARBARA, Calif., June 26, 2025 /PRNewswire/ -- MEI Micro, Inc. is…
‘Haven of Hope’ – Shelter Home for Underprivileged Cancer Patients Inaugurated in Kochi
The 'Haven of Hope' building, built under South Indian Bank's CSR initiative…
Essential Pharma appoints experienced pharmaceutical leaders Simon Ramsden and Rob Smith to leadership team
Essential Pharma appoints experienced pharmaceutical leaders Simon Ramsden and Rob Smith to…
ReCerf Receives its CE Mark, Advancing Access to Ceramic Hip Resurfacing Across Europe
LEATHERHEAD, England, July 3, 2025 /PRNewswire/ -- MatOrtho® is proud to announce…
Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine
Data presented simultaneously at the American Diabetes Association’s® 85th Scientific Sessions, showed…
Draig Therapeutics Launches with $140 Million (107 Million) Total Investment to Advance its Portfolio of Next-Generation Therapies for Major Neuropsychiatric Disorders
Clinical-stage company led by world-class team targeting core neurotransmission pathways underlying neuropsychiatric…
AVEROA receives European marketing authorization for XOANACYL, an Oral Therapy for Chronic Kidney Disease (CKD)
XOANACYL is an oral therapy designed to address critical challenges in CKD,…
Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study
EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal…